Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abatacept

National Institute for Health and Care Excellence NICE logo

NICE backs BMS’ Opdivo for melanoma

Recommendation comes despite the Institute rejecting the drug for lung cancer

Brain cancer glioblastoma

Glioblastoma market set for ‘meteoric rise’

Sales of treatments for rare brain cancer predicted to reach $3.3bn by 2024

Sanofi reception

Sanofi and Novartis snap up immuno-oncology candidates

Separate licensing deals see the firms look to catch up with the category's leaders

- PMLiVE

Mylan buys into six biosimilars, including Orencia candidate

Deal with Momenta bolsters biosimilars pipeline for new products

Roche Basel Switzerland

Roche prepares to file atezolizumab for bladder cancer

Imminent submission to the FDA after additional positive phase II trial results

Free Thinking: From promise to practice: immuno-oncology in action

This white paper explores the global outlook for new immunotherapy products, referencing key opinion leaders and payers to investigate how these products are faring both clinically and financially. Immuno-oncology therapies that...

Research Partnership

- PMLiVE

Baxalta inks $1.6bn immuno-oncology deal with Symphogen

Comes as the company's takeover negotiations with Shire continue

- PMLiVE

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

- PMLiVE

NHS patients set to be denied Opdivo and Kadcyla

NICE rejects BMS and Roche cancer treatments

Bristol-Myers Squibb (BMS) building

Bump in the road slows momentum for BMS’ Opdivo

FDAturns down the cancer treatment for a form of melanoma

Bristol-Myers Squibb (BMS) building

Opdivo cleared for kidney cancer and first-line melanoma

First drug to show survival benefit in kidney cancer since 2007

Bristol-Myers Squibb (BMS) building

BMS closer to kidney cancer approval for Opdivo

Wins priority review for renal cell carcinoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links